Eur J Anaesth:外科ICU围术期血清乳酸水平与术后90天死亡率:回顾性研究

2020-01-28 anesthGH 罂粟花”微信号

术后转入ICU的患者中,较高的围手术期乳酸水平与90天死亡率增加有关。术后0~3天的乳酸峰值水平对这种相关性的影响最为显著。

背景与目的

关于术前和术后乳酸峰值水平与外科ICU患者死亡率的关系,目前还缺乏足够的研究。本研究旨在探讨外科ICU患者围术期乳酸水平与术后90天死亡率的关系。

方  法

选取2012年1月至2017年12月期间,术后转入同一所三级学院型医院ICU的成年患者进行回顾性队列研究。根据以下血清乳酸水平评估90天死亡率的危险比:术前乳酸水平、术后0~3天乳酸峰值、术后0~3天乳酸水平与术前乳酸水平的δ值。采用多变量Cox回归和受试者工作特征曲线分析数据。

结 果

本研究共纳入9248名患者,其中2511例、8690例和1958例分别测量了术前乳酸水平、术后0~3天乳酸水平和这两个时间点的乳酸水平。术后0~3天的乳酸峰值水平和乳酸δ值均增加1 mmol/ L时,90天死亡率分别增加15%(危险比 1.15;95%CI 1.11~1.19;p<0.001)和14%(危险比 1.14;95%CI 1.11~1.18;P<0.001);术前乳酸水平与90天死亡率无显着相关性(P=0.069)。经受试者工作特征曲线分析,术后0~3天乳酸峰值曲线下面积(0.72,95%CI 0.70~0.74)大于术前乳酸峰值曲线下面积(0.58,95%CI 0.56~0.60)。

结 论

术后转入ICU的患者中,较高的围手术期乳酸水平与90天死亡率增加有关。术后0~3天的乳酸峰值水平对这种相关性的影响最为显着。

原始出处:

Oh TK, Song IA, Jeon YT.  Peri-operative serum lactate level and postoperative 90-day mortality in a surgical ICU A retrospective association study.[J].Eur J Anaesthesiol. Jan,2020; 37 (1): 31-37.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633554, encodeId=c22316335540b, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Sep 28 18:20:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051506, encodeId=336d2051506b8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 14:20:00 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275455, encodeId=e9d712e54557f, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Jan 30 05:20:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585697, encodeId=0fba158569ec4, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Thu Jan 30 05:20:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
    2020-09-28 AspirantSuo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633554, encodeId=c22316335540b, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Sep 28 18:20:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051506, encodeId=336d2051506b8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 14:20:00 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275455, encodeId=e9d712e54557f, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Jan 30 05:20:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585697, encodeId=0fba158569ec4, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Thu Jan 30 05:20:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633554, encodeId=c22316335540b, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Sep 28 18:20:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051506, encodeId=336d2051506b8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 14:20:00 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275455, encodeId=e9d712e54557f, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Jan 30 05:20:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585697, encodeId=0fba158569ec4, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Thu Jan 30 05:20:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633554, encodeId=c22316335540b, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Sep 28 18:20:00 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051506, encodeId=336d2051506b8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 18 14:20:00 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275455, encodeId=e9d712e54557f, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Thu Jan 30 05:20:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585697, encodeId=0fba158569ec4, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Thu Jan 30 05:20:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

相关资讯

脊柱外科:腰椎滑脱你怕了吗

腰椎滑脱是由于先天性发育不良、创伤、劳损等多种原因造成相邻椎体骨性连接异常,而发生的上位椎体与下位椎体部分或全部滑移,表现为腰骶部疼痛、坐骨神经受累、间歇性跛行等症状的疾病。

手术前后,这两个检验至关重要,千万不要忘记!

由于手术是典型的开放性治疗手段,对患者机体本身同时会产生强烈的应激反应从而导致炎症反应的发生,且因手术过程中会造成机体损伤、出血等,一旦没有得到有效控制,术后可能出现各种并发症,其中典型的并发症即为术后感染。降钙素原(PCT)作为临床常用的感染标志物,在外科手术领域应用也较为普遍,其特异性强,在当下联合检测的趋势下[1-2],敏感性强的白介素6(IL-6)是它的最好搭档。由于外科手术在围手术期对患

胡盛寿院士回顾中国70年心血管外科发展:从艰难起步,到“中国制造”!推动精准诊疗进基层,助力健康中国梦 ——辉瑞与金域医学在进博会正式签约

今年正值新中国70周年。70年沧桑巨变。阜外医院院长胡盛寿院士指出,对于我国心血管外科的发展而言,这70年,就是一代代心外科工作者从无到有的砥砺前行,从弱到强的锐意进取。凭借这种坚韧,我国心外科工作者将心血管外科的发展推向了前所未有的高度。缅怀先辈,致敬学科先锋,激励自己,未来还需全体都有负重前行,再攀高峰,再创佳绩。 学科探索期(1949~1979年):艰苦卓绝中揭开心血管快速发展序幕

JACC:低外科风险AS患者TAVR依旧是一个更好的选择

对于低外科手术风险的严重主动脉瓣狭窄(AS)患者,经导管主动脉瓣置换术(TAVR)较外科手术的术后1年死亡风险、卒中和再住院风险更低。然而,治疗策略对患者健康状态的影响尚不清楚。本研究的目的旨在比较和评估接受TAVR和外科手术治疗的低风险AS患者的术后健康状态。本研究纳入了PARTNER 3临床试验中的1000名低风险AS患者,并将其随机分成经股TAVR组和外科组,并在基线时、术后1月、6月和12

王永胜:2019年乳腺癌外科治疗研究进展盘点

 外科治疗是乳腺癌综合治疗的重要手段,也是乳腺癌全程管理的关键步骤。随着乳腺癌外科治疗相关研究的开展,在乳腺癌保乳手术、前哨淋巴结活检和乳房重建等方面均有许多重要研究进展,本文针对2019年乳腺癌外科治疗的研究进展进行了相关汇总。 乳腺癌保乳手术 随着乳腺癌患者对生活质量的要求不断增加,乳腺癌保乳手术的比例在不断增长,乳腺癌保乳手术切缘的检查方法一直是乳腺外科临床研究的重

外科临床研究方法学指引——IDEAL框架及指南介绍与解读

外科临床研究是临床实践的重要组成部分,也是医学界最富有创新精神的领域之一。过去几个世纪以来,“外科手术一直是医生手中最强大的研究武器”[1]。炎症、愈合、感染、免疫等大量的医学知识都来源于外科治疗。同时,外科手术仍然是缺血性疾病、创伤、肿瘤等许多疾病不可或缺的治疗方法。据不完全统计,全球每年约有2.34亿例手术,包括6300万人接受创伤手术,3100万人接受肿瘤切除治疗,1000万人接受妊娠相